Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes - MRC-ILA-HEART study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-001767-31-GB

Enrollment

186

Registered

2008-02-20

Start date

2007-03-21

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

We wish to investigate Acute coronary syndromes (ACS). These are caused by blockages in the main arteries that supply the heart as a result of a process called atherosclerosis. These blockages prevent blood flow down the artery and therefore prevent the heart muscle getting the blood and oxygen that it needs to survive and function. They account for 15% of all deaths in the UK and are associated with considerable long term consequences among survivors. MedDRA version: 8.1

Interventions

Trade Name: Kineret Product Name: Kineret Pharmaceutical Form: Solution for injection INN or Proposed INN: ANAKINRA CAS Number: 14309092

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Acute severe cardiac chest pain consistent with an acute coronary syndrome 2) =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1) 220µmol/L 11) Pregnancy or suspected pregnancy (any potential female participant of child bearing age will need a negative pregnancy test prior to study entry) 12) Eosinophilia 13) anti-TNF biologies 14) Active infection 15) Malignancy

Design outcomes

Primary

Measure	Time frame
Secondary Objective: ;Primary end point(s): The primary endpoint will be the difference in the area under the curve of serum hsCRP over the first 7 days between the treatment and the placebo group. ;Main Objective: To determine whether treatment of Acute Coronary Syndrome (ACS) /Non ST Elevation mycardial infarction (ACS are classified by the presenting ECG: patients with persistent ST elevation myocardial infarction (STEMI) generally require early reperfusion, whereas those with non ST-elevation (NSTEMI) ACS require early risk stratification and revascularisation as necessary). with IL-1ra alter the inflammatory process involved in this condition	—

Measure

Time frame

Secondary Objective: ;Primary end point(s): The primary endpoint will be the difference in the area under the curve of serum hsCRP over the first 7 days between the treatment and the placebo group. ;Main Objective: To determine whether treatment of Acute Coronary Syndrome (ACS) /Non ST Elevation mycardial infarction (ACS are classified by the presenting ECG: patients with persistent ST elevation myocardial infarction (STEMI) generally require early reperfusion, whereas those with non ST-elevation (NSTEMI) ACS require early risk stratification and revascularisation as necessary). with IL-1ra alter the inflammatory process involved in this condition

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026